Results 121 to 130 of about 82,032 (316)

Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US

Haemophilia, EarlyView.
ABSTRACT Introduction Despite available prophylactic therapies for haemophilia A, breakthrough bleeding and consequent pain and joint damage still occur. Aim To provide insights into the unmet treatment needs of people with moderate‐to‐severe haemophilia A in the US.
Allison P. Wheeler, Lauren E. Amos, Shveta Gupta, Sylvie Bozzi, Gandarvaka Miles, Kalyani Hawaldar, Andrew Wilson, Gillian Hanson, Emily Cibelli, Amanda Wilson, Siddhi Umarje, Anne‐Laure Tardy, Jennifer Dumont, Graham Neill, Alix Arnaud   +14 more
wiley   +1 more source

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban

Haematologica, 2018
Ida Martinelli, Maria Abbattista, Paolo Bucciarelli, Armando Tripodi, Andrea Artoni, Francesca Gianniello, Cristina Novembrino, Flora Peyvandi   +7 more
doaj   +1 more source

Hemophilia treatment and transfusion medicine

Zhongguo shuxue zazhi
The improvement of hemophilia treatment is attributed to the development of transfusion medicine, and the discovery of cryoprecipitate has opened up a new era of hemophilia treatment, laying the foundation for the development of modern hemophilia ...
FANG Yunhai, CHENG Yan, ZHANG Xinsheng
doaj   +1 more source

Budget impact analysis of use of BPA anti-inhibitor coagulant complex (aicc) and eptacog alfa [activated] in the prophylaxis of bleedings in inhibitor hemophilia patients [PDF]

, 2017
V.G. Serpik, R.I. Yagudinа
openalex   +1 more source

Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. [PDF]

, 2019
BackgroundIn the United States Hepatitis C virus (HCV) viral clearance is estimated to range between 20 and 30%. The objective of this study was to estimate the frequency of HCV clearance and identify correlates of viral clearance among patients newly ...
Baik, Yeonsoo, Chew, Kara W, He, Di, Javanbakht, Marjan, Kimble, Mabel Michille, Klausner, Jeffrey D, Ramirez, Samantha, Saab, Sammy, Stafylis, Chrysovalantis   +8 more
core  

Performing Large‐Scale Genetic Analysis in the Bleeding Disorders Community

Haemophilia, EarlyView.
ABSTRACT Inherited bleeding disorders encompass a diverse group of conditions caused by genetic defects affecting coagulation factors, fibrinogen, von Willebrand factor, or platelet function. Despite major advances in quantitative and functional laboratory assays, a substantial diagnostic gap remains, particularly in patients with mild or atypical ...
Anna R. Blankstein, Sterre P. E. Willems, Saskia E. M. Schols, Rosanna Asselta, Gillian Lowe, Neil V. Morgan, Paula D. James   +6 more
wiley   +1 more source

PB1544 Bleeding Manifestations in Mothers with Hemophilia (Before Knowing Their Diagnosis): A Retrospective Analysis

, 2023
B. Diaz Jordan
openalex   +1 more source

Maximum Likelihood Estimation of the Multivariate Normal Mixture Model [PDF]

The Hessian of the multivariate normal mixture model is derived, and estimators of the information matrix are obtained, thus enabling consistent estimation of all parameters and their precisions.
Boldea, Otilia, Magnus, Jan R.
core   +1 more source

Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients

Haemophilia, EarlyView.
ABSTRACT Introduction The 2021 ASH/ISTH/NHF/WFH VWD diagnosis guidelines recommend Type 1 VWD diagnoses for patients with (a) VWF <0.30 IU/mL or (b) ‘Low VWF’ 0.30–0.50 IU/mL with the presence of abnormal bleeding. This recommendation recategorizes ‘Low VWF’ patients with abnormal bleeding into Type 1 VWD.
Michael Dong, Joanna Larson, Sepideh Saroukhani, Miguel Escobar, Lakshmi Srivaths   +4 more
wiley   +1 more source

66. Effective Treatment of Hemophilia A Using Hematopoietic Stem Cell Transplantation and a Bioengineered Factor VIII Transgene [PDF]

, 2012

openalex   +1 more source